Maintenance Dovitinib for Colorectal and Pancreas Cancer

Inclusion Criteria: * Patients with a confirmed diagnosis of: 1. Stage 4 colon cancer either s/p metastasectomy or post-initial chemotherapy or maintenance "standard of care", either involving 5-fluorouracil/leucovorin (5-FU/LV) alone or continual bevacizumab alone. Patients in maintenance cohort must have had 2 consecutive CT scans showing stable disease and not be experiencing significant prior treatment-related toxicity above Grade 1. 2. Pancreas cancer, either s/p resection and adjuvant chemotherapy or locally advanced pancreas cancer s/p chemotherapy and radiation. Initial chemotherapy or radiation therapy may have been stopped between 2 weeks and 2 months prior to study start, and patients must have recovered from prior treatment related toxicity to grade 1 or less. * Prior surgery, including tumor resection or metastasectomy must have been performed at least 4 weeks prior to study enrollment. * No concomitant anti-cancer treatment is allowed * Age \>/= 18 years * Performance status of 0-1 * Adequate hepatic, bone marrow, and renal function * Partial thromboplastin time (PTT) must be \</= 1.5 x upper normal limit of institution's normal range and INR (International Normalized Ratio) \< 1.5. * Life expectancy \>/= 4 months for maintenance cohorts and \>/= 6 months for adjuvant cohorts * Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and must not be lactating. * Subject is capable of understanding and complying with protocol demands and able to sign and date the informed consent Exclusion Criteria: * Women of child-bearing potential, who are biologically able to conceive, not employing two forms of highly effective contraception or who are pregnant. * Women who are breast-feeding * Fertile males unwilling to use contraception * Patients with brain metastases or any history of brain metastases * Patients who have undergone major surgery (e.g., intra-thoracic, -abdominal, or -pelvic) \</= 4 weeks prior to starting study treatment or who have not recovered from such therapy * Patients with a history of pulmonary embolism, or untreated deep vein thrombosis within the past 6 months * Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of dovitinib * The subject has had another active malignancy within the past 5 years except for cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin. * Patients who have received the last administration of an anticancer therapy including chemotherapy, immunotherapy, hormonal therapy and monoclonal antibodies \</= 2 weeks prior to starting the study drug, or who have not recovered from the side effects of such therapy * Cirrhosis, chronic active hepatitis or chronic persistent hepatitis * Patients who are currently receiving prasugrel * No concurrent use of isoniazid, labetolol, trovafloxacin, tolcapone, and felbamate * No concurrent use of other investigational drugs or antineoplastic therapies. * Patients with impaired cardiac function or clinically significant cardiac diseases.